Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Forte Biosciences ...
Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27. FBRX saw significant price movement beginning June 29, weeks before the public announcement. Both FBRX and...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Forte Biosciences ...
Forte Biosciences stock soars on a $2.2 billion takeover proposal from Argenx. But is there any further upside left in FBRX shares? Let’s find out!
Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth ...
Barchart Research What to Expect from ARGX Earnings ARGX Generated July 22, 2026 Current Price $851.72 EPS Estimate $$6.13 Consensus Rating Strong Buy Average Move 5.01% Argenx's Autoimmune Expansion Beyond...
argenx (NASDAQ:ARGX) Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profitability...
Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth...
With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.
argenx (NASDAQ:ARGX) reported first-quarter 2026 results highlighting continued commercial growth for VYVGART and progress across multiple late-stage pipeline programs, while newly appointed CEO Karen...